Uncategorized
Fewer anti-VEGF injections needed over time
BOSTON — A real-world look at the treat-and-extend regimen of anti-VEGF agents for treating neovascular age-related macular degeneration showed improved vision in patients with fewer injections per year, according to a poster presented at the American Society of Retina Specialists meeting. Arsh ad M. Khanani, MD, and colleagues presented a retrospective evaluation of the 4-year results of the RENO study, which evaluated the real-world treatment outcomes of intravitreal Lucentis (ranibizumab, Genentech), Eylea (aflibercept, Regeneron) or Avastin (bevacizumab, Genentech) given as-needed for treating wet AMD.